Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005081 · ClinicalTrials.gov registry record · Phase 2
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005081: Completed Phase 2 study, sponsored by Duke University.
NCT00005081 is a Phase 2 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005081, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining carmustine and O6-benzylguanine in treating patients who have recurrent or progressive glioma.
Interventions
- DRUG O6-benzylguanine
- DRUG carmustine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
What the finished NCT00005081 record still lists
NCT00005081 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which O6-benzylguanine is the first listed.
NCT00005081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005081 about?
NCT00005081 is a clinical study titled "Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining carmustine and O6-benzylguanine in treating patients who ha...
What is the current status of trial NCT00005081?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00005081?
The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00005081?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia